IMA-AIM can provide you with detailed data on the health care system in Belgium. Their data collection includes information on the reimbursed care and medicines of the 11 million citizens insured in our country. The data is collected by the 7 health insurance funds and processed, analysed and made available for research by IMA-AIM.

The seven health insurance funds in Belgium collect a lot of data about their members in order to be able to carry out their tasks. IMA-AIM brings these data together in databases for the purpose of analysis and research. The databases contain three types of data: population data (demographic and socio-economic characteristics), information about reimbursed health care and information about reimbursed medicines.

The Permanent Sample (EPS) is a longitudinal dataset containing data from the Population, Health Care and Pharmanet databases, as well as data on hospitalisations. The data are available in separate datasets per calendar year. The aim of EPS is to make the administrative data of the health insurance funds permanently available to a number of federal and regional partners. More information about the EPS: https://metadata.ima-aim.be/nl/app/bdds/Ps

Success.ai’s Prospect Data for Biotechnology & Pharmaceutical Innovators Globally provides a powerful dataset designed to connect businesses with key players driving innovation in the biotech and pharmaceutical industries worldwide. Covering companies engaged in drug development, biotechnology research, and life sciences innovation, this dataset offers verified profiles, professional histories, work emails, and phone numbers of decision-makers and industry leaders.

With access to over 700 million verified global profiles and 30 million company profiles, Success.ai ensures your outreach, market research, and partnership efforts are powered by accurate, continuously updated, and AI-validated data. Supported by our Best Price Guarantee, this solution is indispensable for navigating the fast-evolving biotech and pharmaceutical landscape.

Why Choose Success.ai’s Prospect Data for Biotech and Pharmaceutical Innovators?

1. Verified Contact Data for Industry Professionals

   • Access verified work emails, phone numbers, and LinkedIn profiles of executives, R&D leads, compliance officers, and procurement managers in the biotech and pharmaceutical sectors.
   • AI-driven validation ensures 99% accuracy, reducing bounce rates and maximizing communication efficiency.

2. Comprehensive Coverage Across Global Markets

   • Includes profiles of professionals and companies from North America, Europe, Asia-Pacific, and other emerging biotech and pharmaceutical markets.
   • Gain insights into global industry trends, drug development pipelines, and regional innovations.

3. Continuously Updated Datasets

   • Real-time updates capture leadership changes, research breakthroughs, funding activities, and regulatory compliance updates.
   • Stay ahead of market developments and align your strategies with industry dynamics.

4. Ethical and Compliant

   • Adheres to GDPR, CCPA, and other global privacy regulations, ensuring responsible use of data and compliance with legal standards.

Data Highlights:

• 700M+ Verified Global Profiles: Engage with decision-makers, researchers, and executives in biotech and pharmaceutical industries worldwide.
• 30M Company Profiles: Access detailed firmographic data, including revenue ranges, research capacities, and operational footprints.
• Professional Histories: Gain insights into the expertise, career progressions, and roles of professionals driving innovation.
• Leadership Contact Information: Connect directly with CEOs, R&D heads, regulatory managers, and other key stakeholders shaping the future of life sciences.

Key Features of the Dataset:

1. Decision-Maker Profiles in Biotech and Pharmaceuticals

   • Identify and engage with professionals leading research, clinical trials, supply chains, and compliance efforts.
   • Target individuals responsible for strategic decisions in drug development, technology integration, and regulatory adherence.

2. Advanced Filters for Precision Targeting

   • Filter professionals and companies by industry focus (biotech, generics, vaccines), geographic region, revenue size, or workforce composition.
   • Tailor campaigns to address specific needs, such as drug discovery, manufacturing scalability, or market entry.

3. Research and Innovation Insights

   • Access data on research priorities, product pipelines, and innovation trends across global biotech and pharmaceutical sectors.
   • Leverage these insights to position your offerings effectively and uncover new opportunities.

4. AI-Driven Enrichment

   • Profiles enriched with actionable data enable personalized messaging, highlight unique value propositions, and improve engagement outcomes with industry professionals.

Strategic Use Cases:

1. Sales and Lead Generation

   • Present products, services, or technologies that accelerate R&D, streamline production, or ensure compliance to biotech and pharmaceutical companies.
   • Build relationships with procurement teams, regulatory managers, and R&D heads managing budgets and resource allocation.

2. Market Research and Competitive Analysis

   • Analyze global trends in biotechnology and pharmaceuticals to guide product innovation and strategic planning.
   • Benchmark against competitors to identify market gaps, emerging niches, and high-growth opportunities.

3. Partnership Development and Licensing

   • Engage with organizations seeking strategic partnerships, co-development opportunities, or licensing agreements for drug development.
   • Foster alliances that drive mutual growth and innovation in life sciences.

4. Regulatory Compliance and Risk Mitigation

   • Connect with compliance officers and legal professionals overseeing regulatory adherence, clinical trials, and product approvals.
   • Offer solutions that simplify compliance reporting, risk management, and quality assurance processes.

Why Choose Success.ai?

1. Best Price...

There is a completed file for each month. FOI8592 has 2 files (February 2019 and March 2019) Source System – ISP (National MIS Files) NHSBSA Prescription Services process prescriptions for Pharmacy Contractors, Appliance Contractors, Dispensing Doctors and Personal Administration with information then used to make payments to pharmacists and appliance contractors in England for prescriptions dispensed in primary care settings (other arrangements are in place for making payments to Dispensing Doctors and Personal Administration). This involves processing over 1 billion prescription items and payments totalling over £9 billion each year. The information gathered from this process is then used to provide information on costs and trends in prescribing in England and Wales to over 25,000 registered NHS and Department of Health and Social Care users. This report consists of a management information file detailing monthly Community Pharmacy and Appliance Payments by type of payment and contractor account. Payments include all drug costs, fees, patient charges, locally authorised payments, etc. Other details such as the numbers of items dispensed, patient’s charges collected are also included. The management information file reflects the contractor's payment and prescription data associated with the sustainability and transformation partnerships (STPs) structure at the relevant payment date. The data contained within the files can be interpreted correctly by using the ‘MIS Glossary’ available under ‘Management Information Spreadsheet (MIS) Report’ at https://www.nhsbsa.nhs.uk/information-services-portal-isp/isp-report-information . The data in column METHADONE PAYMT and ADD FEE-2E within the Pharmacy dataset have been removed following Information Governance policy. Appliance Contractors data within the MIS- Report shows data for the following month. (E.g. MIS-Report for January 19 will show February 19 Appliance Contractor data). Previous requests and months provided – please add new requests to this.

Under Section 21 of the Act, we are not required to provide information in response to a request if it is already reasonably accessible to you. The information you requested is available from web link: https://opendata.nhsbsa.net/dataset/foi-23358 Data for January 2022 and February 2022 A copy of the information is attached. NHS Prescription Services process prescriptions for Pharmacy Contractors, Appliance Contractors, Dispensing Doctors and Personal Administration with information then used to make payments to pharmacists and appliance contractors in England for prescriptions dispensed in primary care settings (other arrangements are in place for making payments to Dispensing Doctors and Personal Administration). This involves processing over 1 billion prescription items and payments totalling over £9 billion each year. The information gathered from this process is then used to provide information on costs and trends in prescribing in England and Wales to over 25,000 registered NHS and Department of Health and Social Care users. Data source Source System - ISP (National MIS Files) Time period January 2022 and February 2022 The month refers to the month of the report. Please note Appliance Contractors data within the MIS Report shows data for the following month. (E.g. MIS Report for January 2022 will show February 2022 Appliance Contractor data) This dataset FOI25450 has 4 files – January and February 2022 MIS Pharmacy and January and February 2022 MIS Appliance Contractor. This report consists of a management information file detailing monthly Community Pharmacy and Appliance Payments by type of payment and contractor account. Payments include all drug costs, fees, patient charges, locally authorised payments, etc. Other details such as the numbers of items dispensed, patient’s charges collected are also included. The management information file reflects the contractor's payment and prescription data associated with the sustainability and transformation partnerships (STPs) structure at the relevant payment date. The data contained within the files can be interpreted correctly by using the ‘MIS Glossary’ available under ‘Management Information Spreadsheet (MIS) Report’ at https://www.nhsbsa.nhs.uk/information-services-portal-isp/isp-report-information . Disclosure Control The data in column METHADONE PAYMT and ADD FEE-2E within the Pharmacy dataset have been removed following Information Governance policy. February 2022 is the latest MIS report that is available Please note that this request and our response is published on our Freedom of Information disclosure log at:

MCP-MOD is a testing and model selection approach for clinical dose finding studies. During testing, contrasts of dose group means are derived from candidate dose response models. A multiple-comparison procedure is applied that controls the alpha level for the family of null hypotheses associated with the contrasts. Provided at least one contrast is significant, a corresponding set of 'good' candidate models is identified. The model generating the most significant contrast is typically selected. There have been numerous publications on the method. It was endorsed by the European Medicines Agency.

The MCP-MOD procedure can be alternatively represented as a method based on simple linear regression, where 'simple' refers to the inclusion of an intercept and a {\it single} predictor variable, which is a transformation of dose. It is shown that the contrasts are equal to least squares linear regression slope estimates after a re-scaling of the predictor variables. The test for each contrast is the usual t-statistic for a null slope parameter, except that a variance estimate with fewer degrees of freedom is used in the standard error. Selecting the model corresponding to the most significant contrast p-value is equivalent to selecting the predictor variable yielding the smallest residual sum of squares. This criteria orders the models like a common goodness-of-fit test, but it does not assure a good fit. Common inferential methods applied to the selected model are subject to distortions that are often present following data-based model selection.

About this dataset

Context

The dataset tabulates the population of Medicine Park by gender across 18 age groups. It lists the male and female population in each age group along with the gender ratio for Medicine Park. The dataset can be utilized to understand the population distribution of Medicine Park by gender and age. For example, using this dataset, we can identify the largest age group for both Men and Women in Medicine Park. Additionally, it can be used to see how the gender ratio changes from birth to senior most age group and male to female ratio across each age group for Medicine Park.

Key observations

Largest age group (population): Male # 45-49 years (44) | Female # 5-9 years (34). Source: U.S. Census Bureau American Community Survey (ACS) 2018-2022 5-Year Estimates.

Content

When available, the data consists of estimates from the U.S. Census Bureau American Community Survey (ACS) 2018-2022 5-Year Estimates.

Age groups:

• Under 5 years
• 5 to 9 years
• 10 to 14 years
• 15 to 19 years
• 20 to 24 years
• 25 to 29 years
• 30 to 34 years
• 35 to 39 years
• 40 to 44 years
• 45 to 49 years
• 50 to 54 years
• 55 to 59 years
• 60 to 64 years
• 65 to 69 years
• 70 to 74 years
• 75 to 79 years
• 80 to 84 years
• 85 years and over

Scope of gender :

Please note that American Community Survey asks a question about the respondents current sex, but not about gender, sexual orientation, or sex at birth. The question is intended to capture data for biological sex, not gender. Respondents are supposed to respond with the answer as either of Male or Female. Our research and this dataset mirrors the data reported as Male and Female for gender distribution analysis.

Variables / Data Columns

• Age Group: This column displays the age group for the Medicine Park population analysis. Total expected values are 18 and are define above in the age groups section.
• Population (Male): The male population in the Medicine Park is shown in the following column.
• Population (Female): The female population in the Medicine Park is shown in the following column.
• Gender Ratio: Also known as the sex ratio, this column displays the number of males per 100 females in Medicine Park for each age group.

Good to know

Margin of Error

Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.

Custom data

If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.

Inspiration

Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.

Recommended for further research

This dataset is a part of the main dataset for Medicine Park Population by Gender. You can refer the same here

The Clinical Questions Collection is a repository of questions that have been collected between 1991 – 2003 from healthcare providers in clinical settings across the country. The questions have been submitted by investigators who wish to share their data with other researchers. This dataset is no-longer updated with new content. The collection is used in developing approaches to clinical and consumer-health question answering, as well as researching information needs of clinicians and the language they use to express their information needs. All files are formatted in XML.

Time Period Current as of 3 January 2024 Organisation Data The data shows a list of English Pharmacies and their associated Local Pharmaceutical Committee (LPC) Code and Name as of 3 January 2024. This information is provided by the Integrated Care Board (ICB) and is keyed into the Local Payment Application on their behalf. Please note: The information is not static i.e., a pharmacy can move LPC and therefore any extracted data will be ‘as of the date stated’. Data Queries If you have any queries regarding the data provided, or if you plan on publishing the data, please contact foidata@nhsbsa.nhs.uk ensuring you quote the above reference. This is important to ensure that the figures are not misunderstood or misrepresented. If you plan on producing a press or broadcast story based upon the data please contact communicationsteam@nhsbsa.nhs.uk This is important to ensure that the figures are not misunderstood or misrepresented.

Dataset from the bioscience and health technology sector database. The data relates to companies that are active in the UK in the life sciences sectors. These sectors are: Pre- 2015: medical technology medical biotechnology industrial biotechnology pharmaceutical 2015 onwards: medical technology bio-pharmaceuticals The latest report (2018) has been classified as an Official Statistic and is compliant with the Code of Practice for Statistics. 15 September 2021 We have identified several minor errors in the Bioscience and Health Technology Sector Statistics published on the 20 August 2020. Details of these errors (which have been corrected) are as follows. Section 2 – Sector overviews: Several sector breakdowns provide the number of ‘businesses’ in a segment but labelled these as the number of ‘sites’ in the original publication. These errors have been corrected on pages 11, 12 and 13. Section 4 – Digital health & genomics: Overall genomics related activity in the UK is located in 60 sites (previously quoted as 50 on pages 19 and 20). Life Sciences Infographic: The ‘Industry Characteristics’ section states that the top 25 Biopharmaceutical companies and top 30 Medical technology companies globally are responsible for 24% of employment and 37% or turnover in the UK Life Sciences sector. These were quoted as 22% or employment and 35% of turnover in the original publication. We have altered our quality assurance framework to prevent a recurrence of these errors in the future and apologise for any issues they have caused our users.

Request Relating to FOI-01744: I wondered whether it might be possible to determine the items prescribed. I am trying to investigate the breadth of use of the wider formulary for community based V300 prescribers and the data requested was for all items prescribed rather than number of items prescribed. Response NHS Prescription Services process prescriptions for Pharmacy Contractors, Appliance Contractors, Dispensing Doctors, and Personal Administration with information then used to make payments to pharmacists and appliance contractors in England for prescriptions dispensed in primary care settings (other arrangements are in place for making payments to Dispensing Doctors and Personal Administration). This involves processing over 1 billion prescription items and payments totalling over £9 billion each year. The information gathered from this process is then used to provide information on costs and trends in prescribing in England and Wales to over 25,000 registered NHS and Department of Health and Social Care users. Data Source: ePACT2 - Data in ePACT2 is sourced from the NHSBSA Data Warehouse and is derived from products prescribed on prescriptions and dispensed in the Community. The data captured from prescription processing is used to calculate reimbursement and remuneration. It includes items prescribed in England, Wales, Scotland, Northern Ireland, Guernsey / Alderney, Jersey, and Isle of Man which have been dispensed in the community in England. English prescribing that has been dispensed in Wales, Scotland, Guernsey / Alderney, Jersey, and Isle of Man is also included. The Data excludes: • Items not dispensed, disallowed and those returned to the contractor for further clarification. • Prescriptions prescribed and dispensed in prisons, hospitals, and private prescriptions. • Items prescribed but not presented for dispensing or not submitted to NHS Prescription Services by the dispenser. Dataset – This dataset consists of items prescribed on a quarterly basis, split by BNF Presentation, and is limited by prescriber sub-type and ICB (Integrated Care Board). Prescriber sub-types included in the data are Nurse Independent and Community Practitioner Nurse. ICB’s included in the data are Birmingham and Solihull ICB (QHL), Black Country ICB (QUA), Coventry and Warwickshire ICB (QWU), Derby and Derbyshire ICB (QJ2), Herefordshire and Worcestershire ICB (QGH), Leicestershire and Rutland ICB (QK1), Lincolnshire ICB (QJM), Northamptonshire ICB (QPM), Nottingham and Nottinghamshire ICB (QT1), Shropshire, Telford and Wrekin ICB (QOC) and Staffordshire and Stoke-on-Trent ICB (QNC). Please note this data is split into two parts. One file covers March 2019 – December 2021 and the other file covers January 2022 – March 2024

The Drug Product Database (DPD) system captures information on Canadian human, veterinary and disinfectant products approved for use by Health Canada. To facilitate the use of the drug product data, multiple Drug Product files are available. Users can access the complete data set through the “Drug Product” file. Subsets of the data can be accessed in the “Drug Product By …” files. The data in these files are filtered based on the current drug product status. For example, only drug product data for Approved products will be found in the “Drug Product By Approved Status” file.

Compound dataset consisting of structures and bioactivity data (classes) for 512 kinases. Chemical structures are available as InChIKey and bioactivity data as either active (pChEMBL >= 6.5) or inactive (pChEMBL < 6.5) (the meaning of the pChEMBL value can be found on: https://www.ebi.ac.uk/chembl/). The compound structures are chemically standardised by neutralising charges, removing salts, and keeping the largest fragment. The dataset was used in training and validation of statistical models (QSAR and PCM).

The name and postcode of the primary care network or pharmacy contractor. The submission date. The number of vaccines administered. The payment made or to be made. Response A copy of the information is attached. Caveats The NHSBSA calculates payments for Covid Vaccinations to Pharmacies and Primary Care Network (PCN) providers in England. Covid vaccination data is keyed in via Point of Care (POC) Systems and they transferred to the NHSBSA Manage Your Service (MYS) application. Each month, vaccine providers submit claims to request payment based on the data that has been transferred into MYS. To be paid in a timely fashion such claims must be submitted during a specified declaration submission period. Should claims be submitted outside the submission period they will be processed in the following period. Data is limited to 'paid' vaccinations in this request. When considering the nature of the vaccine data there are several ways it can be reported over time: Administration Month - This is the month in which the vaccine was administered to the patient. Payment Month - This is the month in which the payment was made dispenser of the vaccine. Note that all payments for Pharmacies are paid one month later than those for PCN providers. Keying Month - This is the month in which the vaccine record first appeared on the MYS system. Submission/Claim Month - This is the month in which the claim for payment for a vaccination occurred. For example, suppose that a PCN patient is given a covid vaccination dose 1 in January (Administration Month) and then the paper record of this is misplaced for a while. The record is found and keyed into a POC system during February (Keying Month). The Provider is allowed to claim for keying during February in the first 5 days of March, but they're a little late and authorise the claim on the 7th of March (Submission Month). As the claim is outside the submission window it is not paid in March, it will instead be processed during April (Payment Month). Another example could be a Pharmacy patient given a covid vaccination dose 1 in January (Administration Month), keyed in January (Keying Month), then submitted in February (Submission Month) and then payments are calculated in February, however as this is for a pharmacy the payments are held back and not paid until March (Payment Month). For the purposes of this request, we have chosen to report by Administration Month. Data included in this request is limited to covid vaccinations carried out by Pharmacies and co administered flu and covid vaccinations carried out by Primary Care Network (PCN) providers in England. Data included in this request is also limited to vaccinations administered between September 2023 to November 2023 inclusive. The latest data used is a snapshot of the MYS system data that was taken on 7th December 2023. This is the snapshot of data taken after the November 2023 submission period that was used to calculate payments. Pharmacy name and address are as held at this date. This payment data does not include any adjustments made by NHSBSA Provider Assurance as part of post payment verification exercise. These adjustments are made at account level and may relate to several months of activity. Payment data includes payments made and those scheduled for payment in the future. Payments comprise an Item of Service fee and potentially a Supplementary fee. Payments do not relate to the value of the drugs dispensed. The submission date is the date that all doses were submitted with an associated declaration. The total used for the payment calculation may not match the totals shown in 'live' POC systems or MYS that continue to receive updates after the snapshot used to calculate payments was taken. Vaccination records are limited to those which have been associated with a declaration submission. This may include late submission declarations received after the deadline for declarations such records are not processed until the next month. Please note that some vaccinations attract a supplementary fee, so it is not possible to determine the number of vaccinations by dividing the total paid by the basic Item of Service (IoS) fee. It is possible for new records from old administration months to be entered in the future, thus the totals here for each administration month could change when more data is processed.

Under the Freedom of Information Act 2000, I request the following information: The number of individuals of all ages who were prescribed contraceptives in the financial years 2019-2020, 2021-2020, 2020-2021, 2021-2022 and 2022-2023 in community settings (GP surgeries and pharmacies) broken down by contraceptive method. I would also like the proportion these represent of contraception users. For example, X proportion of those on contraception are using the Mirena coil. If possible, I would also appreciate if this were broken down by age of those prescriptions too. To clarify, I mean patients. I also mean both contraceptive drugs and appliances/devices Response A copy of the information is attached. Please read the following information to ensure correct understanding of the data. Fewer than five Please be aware that I have decided not to release the full details where the total number of individuals falls below five. This is because the individuals could be identified, when combined with other information that may be in the public domain or reasonably available. This information falls under the exemption in section 40 subsections 2 and 3 (a) of the Freedom of Information Act (FOIA). This is because it would breach the first data protection principle as: a - It is not fair to disclose individual’s personal details to the world and is likely to cause damage or distress. b - These details are not of sufficient interest to the public to warrant an intrusion into the privacy of the individual. Please click the weblink to see the exemption in full: www.legislation.gov.uk/ukpga/2000/36/section/40 NHS Business Services Authority (NHSBSA) - NHS Prescription Services process prescriptions for Pharmacy Contractors, Appliance Contractors, Dispensing Doctors, and Personal Administration with information then used to make payments to pharmacists and appliance contractors in England for prescriptions dispensed in primary care settings (other arrangements are in place for making payments to Dispensing Doctors and Personal Administration). This involves processing over one billion prescription items and payments totalling over £9 billion each year. The information gathered from this process is then used to provide information on costs and trends in prescribing in England and Wales to over 25,000 registered NHS and Department of Health and Social Care (DHSC) users. Data Source: ePACT2 - Data in ePACT2 is sourced from the NHSBSA Data Warehouse and is derived from products prescribed on prescriptions and dispensed in the Community. The data captured from prescription processing is used to calculate reimbursement and remuneration. It includes items prescribed in England, Wales, Scotland, Northern Ireland, Guernsey/Alderney, Jersey, and Isle of Man which have been dispensed in the community in England. English prescribing that has been dispensed in Wales, Scotland, Guernsey/Alderney, Jersey, and Isle of Man is also included. The data excludes: • Items not dispensed, disallowed and those returned to the contractor for further clarification. • Prescriptions prescribed and dispensed in prisons, hospitals, and private prescriptions. • Items prescribed but not presented for dispensing or not submitted to NHS Prescription Services by the dispenser. Dataset - The data is limited to presentations prescribed in BNF sections 0703 Contraceptives and BNF section 2104 Contraceptive Devices. Data is presented at BNF Sub Paragraph and BNF Presentation level. Time Period - Financial years 2019/20, 2020/21, 2021/22, 2022/23 and 2023/24 (April 2023 - January 2024). Data is currently available up to and including January 2024. Organisation Data - The data is for prescribing in England regardless of where dispensed in the community. British National Formulary (BNF) Sub Paragraph and Presentation Code – The BNF Code is a 15-digit code in which the first seven digits are allocated according to the categories in the BNF, and the last eight digits represent the medicinal product, form, strength and the link to the generic equivalent product. NHS Prescription Services has created pseudo BNF chapters, which are not published, for items not included in BNF chapters 1 to 15. Most of such items are dressings and appliances which NHS Prescription Services has classified into four pseudo BNF chapters (20 to 23). Patient Identification - Where patient identifiable figures have been reported they are based on the information captured during the prescription processing activities. Please note, patient details cannot be captured from every prescription form and based on the criteria used for this analysis, patient information (NHS number) was only available for 98.28% of prescription items. The unique patient count figures are based on a distinct count of NHS number as captured from the prescription image. Patient ages are based on the age as captured from the prescription image and relates to the patient's age at the time of prescribing/dispensing. Please note it is possible that a single patient may be included in the results for more than one age band where a patient has received prescribing at different ages during a financial year. The figures for the number of identifiable patients should not be combined and reported at any other level than provided as this may result in the double counting of patients. For example, a single patient could appear in the results for multiple presentations or both financial years. Patient Age - Shows the age of the patient, if recorded. Data Quality for patient age - NHSBSA stores information on the age of the recipient of each prescription as it was read by computer from images of paper prescriptions or as attached to messages sent through the electronic prescription system. The NHSBSA does not validate, verify or manually check the resulting information as part of the routine prescription processing. There are some data quality issues with the ages of patients prescribed the products. The NHSBSA holds prescription images for 18 months. A sample of the data was compared to the images of the paper prescription forms from which the data was generated where these images are still available. These checks revealed issues in the reliability of age data, in particular the quality of the stored age data was poor for patients recorded as aged two years and under. When considering the accuracy of age data, it is expected that a small number of prescriptions may be allocated against any given patient age incorrectly. Application of Disclosure Control to information services (prescriptions) products- ePACT 2 data is not published statistics - it is available to authorised NHS users who are subject to Caldicott Guardian approval. We have no plans to apply disclosure control to data released to ePACT 2 users. These users are under an obligation to protect the anonymity of any patients when reusing this data or releasing derived information publicly. All requests that fall under the FOI process are subject to the NHSBSA Anonymisation and Pseudonymisation Standard. The application of the techniques described in the standard is judged on a case-by-case basis (by NHSBSA Information Governance) in respect of what techniques should be applied. The ICO typically rules on a case-by-case basis too so each case or challenge or appeal is judged on its own merits. FOI rules apply to data that we hold as part of our normal course of business.

A. SUMMARY This dataset includes data on a variety of substance use services funded by the San Francisco Department of Public Health (SFDPH). This dataset only includes Drug MediCal-certified residential treatment, withdrawal management, and methadone treatment. Other private non-Drug Medi-Cal treatment providers may operate in the city. Withdrawal management discharges are inclusive of anyone who left withdrawal management after admission and may include someone who left before completing withdrawal management.

This dataset also includes naloxone distribution from the SFDPH Behavioral Health Services Naloxone Clearinghouse and the SFDPH-funded Drug Overdose Prevention and Education program. Both programs distribute naloxone to various community-based organizations who then distribute naloxone to their program participants. Programs may also receive naloxone from other sources. Data from these other sources is not included in this dataset.

Finally, this dataset includes the number of clients on medications for opioid use disorder (MOUD).

The number of people who were treated with methadone at a Drug Medi-Cal certified Opioid Treatment Program (OTP) by year is populated by the San Francisco Department of Public Health (SFDPH) Behavioral Health Services Quality Management (BHSQM) program. OTPs in San Francisco are required to submit patient billing data in an electronic medical record system called Avatar. BHSQM calculates the number of people who received methadone annually based on Avatar data. Data only from Drug MediCal certified OTPs were included in this dataset.

The number of people who receive buprenorphine by year is populated from the Controlled Substance Utilization Review and Evaluation System (CURES), administered by the California Department of Justice. All licensed prescribers in California are required to document controlled substance prescriptions in CURES. The Center on Substance Use and Health calculates the total number of people who received a buprenorphine prescription annually based on CURES data. Formulations of buprenorphine that are prescribed only for pain management are excluded.

People may receive buprenorphine and methadone in the same year, so you cannot add the Buprenorphine Clients by Year, and Methadone Clients by Year data together to get the total number of unique people receiving medications for opioid use disorder.

For more information on where to find treatment in San Francisco, visit findtreatment-sf.org. 

B. HOW THE DATASET IS CREATED This dataset is created by copying the data into this dataset from the SFDPH Behavioral Health Services Quality Management Program, the California Controlled Substance Utilization Review and Evaluation System (CURES), and the Office of Overdose Prevention.

C. UPDATE PROCESS Residential Substance Use Treatment, Withdrawal Management, Methadone, and Naloxone data are updated quarterly with a 45-day delay. Buprenorphine data are updated quarterly and when the state makes this data available, usually at a 5-month delay.

D. HOW TO USE THIS DATASET Throughout the year this dataset may include partial year data for methadone and buprenorphine treatment. As both methadone and buprenorphine are used as long-term treatments for opioid use disorder, many people on treatment at the end of one calendar year will continue into the next. For this reason, doubling (methadone), or quadrupling (buprenorphine) partial year data will not accurately project year-end totals.

E. RELATED DATASETS Overdose-Related 911 Responses by Emergency Medical Services Unintentional Overdose Death Rates by Race/Ethnicity Preliminary Unintentional Drug Overdose Deaths

Washington’s PMP was created (RCW 70.225 (2007)) to improve patient care and to stop prescription drug misuse by collecting dispensing records for Schedule II, III, IV and V drugs, and by making the information available to medical providers and pharmacists as a patient care tool. Program rules, WAC 246-470, took effect August 27, 2011. The program started data collection from all dispensers October 7, 2011.

Under RCW 70.225.040(5)(a), the department is authorized to publish public data after removing information that could be used directly or indirectly to identify individual patients, requestors, dispensers, prescribers, and persons who received prescriptions from dispensers. The data available here are de-identified, and exclude patient, prescriber, and dispenser related information in alignment with program rules WAC 246-470-080. No requestor information is available here.

Prescriptions excluded from PMP include those dispensed outside of WA State, those prescribed for less than or equal to 24 hours, those administered or given to a patient in the hospital, and those dispensed from a Department of Corrections pharmacy (unless an offender is released with a prescription), an Opioid Treatment Program, and some federally operated pharmacies (Indian Health Services and Veterans Affairs report voluntarily since 2015).

Further information on collection and management of PMP data at DOH can be found at www.doh.wa.gov/pmp/data.

We have considered this request under the Freedom of Information Act 2000 (FOIA 2000) and are issuing a refusal notice under section 17 of the FOIA. The NHSBSA does hold the requested information; however, we consider that this information is exempt from disclosure under section 21 of FOIA. This provides an exemption from the duty to disclose information where this is reasonable accessible to an applicant by other means. This information is already available in the public domain and can be accessed via the NHSBSA website https://opendata.nhsbsa.net/dataset/foi-02624 Please see the following link to view the section 21 in full - https://www.legislation.gov.uk/ukpga/2000/36/section/21 January 2025 I can confirm that the NHSBSA holds the information you have requested and a copy of the information and notes explaining it is attached. Please read the below notes to ensure correct understanding of the data. NHS Prescription Services process prescriptions for Pharmacy Contractors, Appliance Contractors, Dispensing Doctors and Personal Administration with information then used to make payments to pharmacists and appliance contractors in England for prescriptions dispensed in primary care settings (other arrangements are in place for making payments to Dispensing Doctors and Personal Administration). This involves processing over 1 billion prescription items and payments totalling over £9 billion each year. The information gathered from this process is then used to provide information on costs and trends in prescribing in England and Wales to over 25,000 registered NHS and Department of Health and Social Care users. Data source - Source System – Insight Data Warehouse. Time period - January 2025 for the Appliance Contractor file This dataset - This report consists of a management information file detailing monthly Appliance Contractor payments by type of payment and contractor account. Payments include all drug costs, fees, patient charges, locally authorised payments, etc. Other details such as the numbers of items dispensed and patient charges collected are also included. The management information file reflects the contractor's payment and prescription data associated with the Integrated Care Boards (ICBs) structure at the relevant payment date

📈 Daily Historical Stock Price Data for Acumen Pharmaceuticals, Inc. (2021–2025)

A clean, ready-to-use dataset containing daily stock prices for Acumen Pharmaceuticals, Inc. from 2021-07-01 to 2025-05-28. This dataset is ideal for use in financial analysis, algorithmic trading, machine learning, and academic research.

  🗂️ Dataset Overview

Company: Acumen Pharmaceuticals, Inc. Ticker Symbol: ABOS Date Range: 2021-07-01 to 2025-05-28 Frequency: Daily Total Records: 981… See the full description on the dataset page: https://huggingface.co/datasets/khaledxbenali/daily-historical-stock-price-data-for-acumen-pharmaceuticals-inc-20212025.

About this dataset

Context

The dataset tabulates the population of Medicine Bow by gender across 18 age groups. It lists the male and female population in each age group along with the gender ratio for Medicine Bow. The dataset can be utilized to understand the population distribution of Medicine Bow by gender and age. For example, using this dataset, we can identify the largest age group for both Men and Women in Medicine Bow. Additionally, it can be used to see how the gender ratio changes from birth to senior most age group and male to female ratio across each age group for Medicine Bow.

Key observations

Largest age group (population): Male # 55-59 years (32) | Female # 65-69 years (22). Source: U.S. Census Bureau American Community Survey (ACS) 2017-2021 5-Year Estimates.

Content

When available, the data consists of estimates from the U.S. Census Bureau American Community Survey (ACS) 2017-2021 5-Year Estimates.

Age groups:

• Under 5 years
• 5 to 9 years
• 10 to 14 years
• 15 to 19 years
• 20 to 24 years
• 25 to 29 years
• 30 to 34 years
• 35 to 39 years
• 40 to 44 years
• 45 to 49 years
• 50 to 54 years
• 55 to 59 years
• 60 to 64 years
• 65 to 69 years
• 70 to 74 years
• 75 to 79 years
• 80 to 84 years
• 85 years and over

Scope of gender :

Please note that American Community Survey asks a question about the respondents current sex, but not about gender, sexual orientation, or sex at birth. The question is intended to capture data for biological sex, not gender. Respondents are supposed to respond with the answer as either of Male or Female. Our research and this dataset mirrors the data reported as Male and Female for gender distribution analysis.

Variables / Data Columns

• Age Group: This column displays the age group for the Medicine Bow population analysis. Total expected values are 18 and are define above in the age groups section.
• Population (Male): The male population in the Medicine Bow is shown in the following column.
• Population (Female): The female population in the Medicine Bow is shown in the following column.
• Gender Ratio: Also known as the sex ratio, this column displays the number of males per 100 females in Medicine Bow for each age group.

Good to know

Margin of Error

Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.

Custom data

If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.

Inspiration

Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.

Recommended for further research

This dataset is a part of the main dataset for Medicine Bow Population by Gender. You can refer the same here

The Texas Department of Insurance, Division of Workers’ Compensation (DWC) maintains a database of pharmacy medical billing services (SV4). It contains charges, payments, and prescriptions billed on a DWC Form-066, Statement of Pharmacy Services by pharmacies with dates of service more than five years old going back to 2010. For datasets from the past five years, see pharmacy medical billing services (SV4) detail information. The detail section contains information to identify insurance carriers, injured employees, employers, place of service, and diagnostic information. The bill details are individual line items that are grouped in the header section of a single bill. The bill selection date and bill ID must be used to group individual line items into a single bill. Find more information in our pharmacy medical billing services (SV4) detail data dictionary. See pharmacy medical billing services (SV4) header information - historical for the corresponding header records related this dataset. Go to our page on DWC medical state reporting public use data file (PUDF) to learn more about using this information.